Aligos Therapeutics Inc
ALGS
Get informed when a big investor buys or sells
+ FollowMarket Cap$34.59M
Close$
$-0.44
106.5% downside
Current Fair Value
106.5% downsideOvervalued by 106.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $34.59 Million |
|---|---|
| Enterprise Value | $7.72 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.45 |
| Beta | 2.26 |
| Outstanding Shares | 10,430,808 |
Return
| Return on Equity | -238.24% |
|---|---|
| Return on Assets | -114.53% |
| Return on Invested Capital | -199.55% |
Valuation & Multiples
| P/E Ratio | -0.77 |
|---|---|
| PEG | 0.85 |
| Price to Sales | 3.39 |
| Price to Book Ratio | 2.26 |
| Enterprise Value to Revenue | 0.25 |
| Enterprise Value to EBIT | -0.1 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.45 |
| Debt to Equity | 0.11 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-1.09
Average shareholder expectationRevenue Estimate
$24.68 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-2.44
Average shareholder expectationRevenue Estimate
$4.85 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 26.68%▼ 1.76% |
|---|---|
| Total Invested | $20.62M▼ 21.27% |
| Investors Holding | 34▼ 5.00% |
ESG Score
No data
About Aligos Therapeutics Inc
80 employeesAligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the discovery and de...